NATALIE OLIVER: Open Payments
NPI 1164194692 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,335 in 103 payments from 10 companies in 2025. Trend: 2023 $1,536 · 2024 $2,267 · 2025 $5,335
Food & beverage: $2,352Consulting: $2,250Travel & lodging: $732
| Company | Payments | Amount |
|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 36 | $3,612 |
| Madrigal Pharmaceuticals | 26 | $680 |
| Gilead Sciences, Inc. | 13 | $445 |
| ORPHALAN INC | 6 | $167 |
| Ipsen Biopharmaceuticals, Inc | 7 | $151 |
| ABBVIE INC. | 9 | $146 |
| Novo Nordisk Inc | 3 | $58 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $30 |
| Mirum Pharmaceuticals, Inc. | 1 | $24 |
| Fujifilm Healthcare Americas Corporation | 1 | $23 |
Products named: TRULANCE, REZDIFFRA, XIFAXAN, CUVRIOR, IQIRVO, MAVYRET, CREON, Wegovy.
Industry payments across TX — which companies pay providers there.
